{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:23Z","timestamp":1786119263105,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/wnf.0b013e3181b3ab16","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T03:16:32Z","timestamp":1259723792000},"page":"311-320","source":"Crossref","is-referenced-by-count":60,"title":["Gabapentin Enacarbil in Restless Legs Syndrome"],"prefix":"10.1097","volume":"32","author":[{"given":"Arthur S.","family":"Walters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clete A.","family":"Kushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Canafax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study.","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1440-1819.2008.01825.x","article-title":"Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: epidemiological survey in Sweden.","volume":"62","author":"Broman","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0149-2918(04)90136-1","article-title":"Evaluating the quality of life of patients with restless legs syndrome.","volume":"26","author":"Abetz","year":"2004","journal-title":"Clin Ther"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","article-title":"Long-term treatment of restless legs syndrome with dopamine agonists.","volume":"61","author":"Ondo","year":"2004","journal-title":"Arch Neurol"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(05)70139-3","article-title":"The restless legs syndrome.","volume":"4","author":"Trenkwalder","year":"2005","journal-title":"Lancet Neurol"},{"key":"R9-2-20210203","first-page":"13","article-title":"Restless legs syndrome: nonpharmacologic and pharmacologic treatments.","volume":"62","author":"Winkelman","year":"2007","journal-title":"Geriatrics"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002826-199704000-00006","article-title":"Treatment of restless legs syndrome with gabapentin.","volume":"20","author":"Adler","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.57.9.1717","article-title":"Treatment of idiopathic restless legs syndrome (RLS) with gabapentin.","volume":"57","author":"Happe","year":"2001","journal-title":"Neurology"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000072882","article-title":"Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.","volume":"48","author":"Happe","year":"2003","journal-title":"Neuropsychobiology"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/sleep\/19.3.224","article-title":"Management of restless legs syndrome with gabapentin (Neurontin).","volume":"19","author":"Mellick","year":"1996","journal-title":"Sleep"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1081\/JDI-120039823","article-title":"Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study.","volume":"26","author":"Micozkadioglu","year":"2004","journal-title":"Ren Fail"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/ajkd.2001.25202","article-title":"A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients.","volume":"38","author":"Thorp","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 (+\/)-1-((alpha-isobutanoyloxyethoxy)carbonyl aminomethyl)-1-cyclohexane acetic acid, a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 (+\/)-1-((alpha-isobutanoyloxyethoxy)carbonyl aminomethyl)-1-cyclohexane acetic acid, a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":"Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/sim.790","article-title":"Comparisons of two-part models with competitors.","volume":"20","author":"Lachenbruch","year":"2001","journal-title":"Stat Med"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1191\/0962280202sm289ra","article-title":"Analysis of data with excess zeros.","volume":"11","author":"Lachenbruch","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0197-2456(84)80014-8","article-title":"Designs for group sequential tests.","volume":"5","author":"Fleming","year":"1984","journal-title":"Control Clin Trials"},{"key":"R28-2-20210203","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure.","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Statis"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.sleep.2006.03.011","article-title":"Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study.","volume":"7","author":"Partinen","year":"2006","journal-title":"Sleep Med"},{"issue":"2","key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","article-title":"A randomized, double-blind, placebo-controlled crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome.","volume":"32","author":"Kushida","year":"2009","journal-title":"Sleep"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1212\/01.WNL.0000120672.94060.F1","article-title":"Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.","volume":"62","author":"Adler","year":"2004","journal-title":"Neurology"},{"key":"R32-2-20210203","first-page":"92","article-title":"Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.","volume":"75","author":"Trenkwalder","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.20257","article-title":"Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.","volume":"19","author":"Walters","year":"2004","journal-title":"Mov Disord"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.sleep.2004.12.002","article-title":"Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.","volume":"6","author":"Bliwise","year":"2005","journal-title":"Sleep Med"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4065\/81.1.17","article-title":"Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.","volume":"81","author":"Bogan","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1212\/WNL.52.5.938","article-title":"Restless legs syndrome improved by pramipexole: a double-blind randomized trial.","volume":"52","author":"Montplaisir","year":"1999","journal-title":"Neurology"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/01.wnl.0000231513.23919.a1","article-title":"Efficacy and safety of pramipexole in restless legs syndrome.","volume":"67","author":"Winkelman","year":"2006","journal-title":"Neurology"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.21261","article-title":"Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study).","volume":"22","author":"Oertel","year":"2007","journal-title":"Mov Disord"},{"issue":"5","key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS.","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"R40-2-20210203","first-page":"26","article-title":"Restless legs syndrome: demographics, presentation, and differential diagnosis.","volume":"62","author":"Hening","year":"2007","journal-title":"Geriatrics"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WNF.0b013e3181b3ab16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:07:55Z","timestamp":1786039675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200911000-00002"}},"subtitle":["A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181b3ab16","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}